Page 295 - 2021_02-Haematologica-web

Letters to the Editor
type I pan-FLT3 inhibitor. Proc Nat Acad Sci U S A.
2014;111(14):5319-5324.
8. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a
uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984- 2992.
9. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433-443.
10. Warkentin AA, Lopez MS, Lasater EA, et al. Overcoming myelo-
suppression due to synthetic lethal toxicity for FLT3-targeted
acute myeloid leukemia therapy. Elife. 2014;3.
11. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic pro-
tein kinase inhibitors SU5416 and SU6668 inhibit the SCF recep- tor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001;97(5):1413-1421.
12.He BL, Shi X, Man CH, et al. Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood, 2014;123(16):2518-2529.
haematologica | 2021; 106(2)
609